Chemo Fails to Boost Survival in Stomach Cancers
showed no significant improvement in outcomes,
11 (HealthDay News) -- Chemotherapy
following surgery does not improve survival
in stomach cancer patients, says
an Italian study.
surgery is the only treatment that can potentially
cure non-metastatic gastric cancer, according
to background information in the study. However,
some recent research has suggested that a
chemotherapy combination of cisplatin, epirubicin,
5-fluorouracil and leucovorin (PELF) improves
outcomes in people with metastatic gastric
cancer. In this study, researchers tested
the PELF combination in patients with localized
gastric cancer. Some of the 258 patients in
the study were treated with surgery only,
while others had surgery followed by chemotherapy.
At a median
follow-up of 72.8 months, there was no statistical
difference between the two groups in terms
of disease-free survival or overall survival.
Disease progression occurred in 47.7 percent
of patients in the surgery/chemotherapy group
and in 51.6 percent of those in the surgery
survival rate was 47 percent in the surgery/chemotherapy
group and 45.3 percent in the surgery group.